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Abstract Enterovirus and parechovirus are a frequent cause
of infection in children. This review is an overview of what is
known from enterovirus and parechovirus infection in chil-
dren and contains information about the epidemiology, path-
ogenesis, clinical presentation, diagnosis, treatment, and prog-
nosis of enterovirus and parechovirus infection in children.
Conclusions: EV and HPeV infections are a frequent cause
of infection in childhood. The clinical presentation is diverse.
RT-qPCR is the best way to detect an EV or HPeV.
Cerebrospinal fluid, blood and feces have the highest sensitivity
for detecting an EVor HPeV. There is no treatment for EVand
HPeV infections. Two vaccines against EV 71 are just licensed
in China and will be available on the private market. Little is
known about the prognosis of EVand HPeV infections.
What is known:
•EVand HPeVare a frequent cause of infection in children.
What is new:
•This review gives a brief overview over EVand HPeV infection in
children.
Keywords Enterovirus . Parechovirus . Overview .
Children . Infection
Historical perspectives [1]
Human enteroviruses (EV) were originally classified accord-
ing to their pathogenicity [2]. The first human enteroviruses
(EV) discovered after poliovirus were the Coxsackie viruses.
They were named according to the first geographical site of
their isolation in New York [3]. A distinction was made be-
tween Coxsackie Aviruses, which were shown to induce flac-
cid paralysis and affect skeletal and heart muscle in mouse
models, and Coxsackie B viruses, which were shown to in-
duce spastic paralysis and affect a wide range of mouse tis-
sues, including the central nervous system, liver, exocrine
pancreas, brown fat, and striated muscle [4]. The name
Echovirus (enteric, cytopathogenic, human, orphan virus)
was then chosen for the viruses [5]. Later, it was found that
individual Echovirus serotypes are associated with a wide
variety of clinical manifestations, as gastro-enteritis, meningi-
tis and respiratory illness [6]. With the discovery of new EV
types, it became increasingly difficult to classify them based
on specific clinical manifestations as serotypes with only a
few molecular differences had a different viral phenotype
leading to highly diverse symptoms. Therefore, since 1974,
new EVs with different serological properties have been num-
bered by their order of identification. More recently, thanks to
molecular typing, the classification of EVs has been adapted
and revised [7]. Moreover, two serologically distinct viruses,
discovered in 1956 during a summer diarrhea outbreak in
American children [8], were originally described as
Echovirus 22 and 23 within the human EVs because of their
clinical and morphological properties. However, they were
shown to be distinct from EVs and other picornavirus groups
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in several features of their genome organization, structure, and
replication and were renamed and reclassified into their own
genus, Parechovirus [9–11].
Picornaviruses
The Picornaviridae family is one of the largest RNA virus
families and contains an array of pathogens that infect both
humans and animals. Picornaviruses are small (∼30 nm), non-
enveloped viruses containing a single-stranded ribonucleic
acid (RNA). The family is classified into 29 genera including
the genus Enterovirus and Parechovirus (Fig. 1).
The genusEnterovirus is divided into 12 species (EVA-J and
Rhinovirus A-C). EVA, B, C andD are found in human, where-
as EV E and F are found in cattle, G in pigs and H in monkeys.
EV-A consists of 25 types, EV-B 63 types, EV-C 23 types and
EV-D of 5 types. The Genus Parechovirus is divided into 2
species (Parechovirus A and B). The species Parechovirus A
consists of 16 types, i.e., human parechovirus (HPeV)-1 to 16.
Parechovirus B (formerly named Ljungan virus) consists of
Ljungan virus types 1 to 4 which infect rodents [12–14]).
Epidemiology of EVand HPeV infections
EVandHPeVare amajor cause of aseptic meningitis in children,
especially in neonates and young infants [6, 15–17]. The inci-
dence of EV and HPeV infections in the Netherlands is not
exactly known, since it is not a notifiable infection. Verboon et
al. described an incidence of 26 per 100.000 neonates
(age≤30 days) [18]. This incidence is probably higher since
only children admitted to a neonatal intensive care unit were
included. In Norway, 40 % of the children below the age of
12 months and 90 % of the children below the age of 2 yeasr
had an EV infection [19]. In the US, the incidence in children
below the age of 90 days varies from 3.2 % in January till 50 %
in August and October [20]. Clearly, EV infections form a
Fig. 1 Classification of the virus
family Picornaviridae. The most
important genera are depicted
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seasonal pattern and the incidence is the highest in the summer
and autumn [20, 21]. The incidence of HPeV infection has been
underestimated, but data shows that HPeVs are at least as prev-
alent as EVs [22]. Serological data indicates that over 90 % of
children have been infected with at least one HPeV type by the
age of 2 years [23–25]. EVand HPeV infections are seen in all
age groups but mainly in children below 1 year of age [23, 26,
27]. HPeV infections are rare in older children and adults, while
EVinfections are regularly seen in older children and adults [28].
Seventy percent of the EV infections reported to the WHO are
children below the age of 10 year [27].
Pathogenesis
Enteroviruses are cytopathic. Much of the associated disease
presumably results from tissue-specific cell destruction but some
disease manifestations, for example, EV exanthemas and myo-
carditis are thought to result from the host immune response to
the infection. Mostly, the actual mechanisms of virus-induced
disease have not been well-characterized [29]. Transmission of
EVs occur through the fecal-oral and transplacental routes and
by respiratory droplets [30, 31]. The primary replication sites of
EV and HPeV are the epithelial cells of the oropharyngeal and
intestinal mucosa. Although some replication may occur in the
nasopharynx with spread to upper respiratory tract lymphatics,
most of the virus is swallowed and transferred to the stomach and
lower gastro-intestinal tract. There, EVs presumably bind to spe-
cific receptors on enterocytes. The virus crosses the intestinal
lining cells reaches the Peyer’s patches in the lamina propria,
where significant viral replication occurs [32]. This is followed
by a viremia that may lead to a secondary site of tissue infection
[29, 33]. Secondary infection of the central nervous system
results in meningitis or encephalitis. Other tissue-specific infec-
tions can result in myocarditis or pleurodynia. Disseminated
infection can lead to exanthemas, nonspecificmyalgias, or severe
multiple organ disease. After a primary EV or HPeV infection,
there is still a possibility of viral shedding in the feces and respi-
ratory system for several weeks [34–37]. Harvala et al. suggested
that the arginine-glycine-aspartic acid (RGD) motif, which par-
ticipates in cell entry, has a significant role in the pathogenesis of
Coxsackievirus A9 infections [35]. Recently, Sin et al. did a
review in understanding the pathogenesis of Coxsackievirus
infections [38]. They concluded that although recent discoveries
have beenmade regarding determinants of tropism, host proteins
involved in replication in target cells, and mechanisms of
Coxsackievirus B pathogenesis; many questions remain
unanswered.
The majority of the pathogenicity studies on HPeV infec-
tion are related to HPeV-1 and HPeV-3 [28]. They suggest that
the different clinical manifestations of the various types of
HPeV may be explained by differences in their biological
characteristics. It seems that HPeV3 lacks the arginine-
glycine-glutamic acid sequence motif at the carboxyl terminus
of VP1 that is characteristic for other HPeVs and is thought to
mediate the use of integrins as cell receptors, suggesting it
may use a different receptor to enter cells with a potentially
different tropism [23]. This unique receptor may explain why
HPeV-3 is associated with neonatal sepsis and central nervous
system infection. In order to verify whether the in vitro repli-
cation kinetics of HPeV-1 and HPeV-3 are related to their
pathogenicity, Westerhuis et al. used real-time polymerase
chain reaction (PCR) to study isolated HPeV-1 and HPeV-3
strains in cultures of gastrointestinal, respiratory and neuronal
cell lines [39]. They found no relationship between the clinical
symptoms and in vitro replication of the HPeV-1 strains, but
the HPeV-3 strains replicated more rapidly in neuronal cells,
suggesting a relationship with its neuropathogenicity. They
also found that HPeV-1 could be efficiently neutralized by
its specific antibody and intravenous immunoglobulins,
whereas most HPeV-3 strains could not be neutralized, which
may explain the milder clinical course of HPeV-1 infections.
Triantafilou et al. made the interesting observation that toll-
like receptors (TLR) 8 and TLR 7 seem to act as host sensors
for HPeV-1 [40]. TLR 8 and 7 are localized in endosomes
where they sense viral genomic RNA which subsequently
leads to the secretion of inflammatory and regulatory cyto-
kines aimed at controlling the infection. Volpe et al. describe
that TLR7 and TLR8 play an important role in the pathogen-
esis of white matter injury with HPeV-3 encephalitis [41].
HpeV3 is taken up by the brain microglia and the single-
stranded RNA (ssRNA) binds to intracellular TLR8 to initiate
the innate immune response. The resulting release of reactive
oxygen and nitrogen species and proinflammatory cytokines
would lead to pre-oligodendrocyte and axonal injury. After
infecting the neurons, the ssRNA of HPeV-3 could active
TLR8 in the cell body, especially in the developing axon
and growth cone (where TLR 8 is most abundant). The result
would be axonal retraction and neuronal apoptosis.
Clinical presentation of EVand HPeV infections
EVs are associated with a great variety of manifestations,
varying from mild respiratory and gastrointestinal infections,
herpangina, and hand-foot-and-mouth disease, to more severe
diseases like pleurodynia, hepatitis, myopericarditis, pancrea-
titis, meningitis, encephalitis, paralysis, and neonatal sepsis
leading to mortality [1, 17, 42–44]. EVs are the most impor-
tant cause for viral meningitis, accounting for approximately
90 % of all cases for which an etiological agent was identified
[32, 45, 46].
The most commonly circulating HPeV, HPeV-1, mainly
causes mild gastrointestinal and respiratory disease although
sometimes in young children more severe disease can be ob-
served [33, 47–49]. Furthermore, HPeVs are the second most
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important cause of viral sepsis-like illness and meningitis in
infants [50–53]. The majority of these cases are caused by
HPeV-3, which is the most pathogenic HPeV type [52, 54].
It is associated with paralysis, neonatal sepsis-like illness, and
sudden death in infected infants [52, 55–59]. HPeVs have
received very little attention from the scientific community
in the past, but continuing reports of HPeV circulation all over
the world are increasing awareness of the clinical significance
of this virus group. The different clinical manifestation of the
different types EVand HPeVmay be explained by differences
in their biological characteristics [28].
Since 2000, there were some outbreaks of severe EV-D68
and EV-D71 infections [60]. EV-D68 mostly give respiratory
symptoms, but an unexpectedly high number of children have
been hospitalized for severe respiratory disease due to EV-
D68, requiring intensive care such as intubation and mechan-
ical ventilation [61]. Enterovirus 71 is a common cause of
hand, foot, and mouth disease and encephalitis but also can
give central nervous system (CNS) involvement and cardio-
pulmonary failure [62].
Laboratory diagnosis of EVand HPeV infections
Reverse-transcriptase real-time quantitative PCR (RT-qPCR)
has been shown to be more sensitive than viral culture in
detecting both EV and HPeV RNA and has become the gold
standard for diagnosing EVand HPeV infections [16, 63–68].
Besides being more sensitive, it is also easier and more rapid
to perform than viral culture [28, 53, 69, 70]. It is also possible
to do a genotyping with RT-qPCR of EVand HPeV [52, 71].
A RT-qPCR can be performed on different body fluids for
example cerebrospinal fluid, nasopharyngeal, blood, urine,
and feces specimens. Cerebrospinal fluid, blood, and feces
have the highest sensitivity for detecting an EVor HPeV [69].
Prevention and treatment [54]
Although EVand HPeVare a frequent cause of serious infec-
tion in children, there are limited tools available to fight these
viruses. Vaccines were only available against Poliovirus [54].
Advances have been made towards the development of a vac-
cine against EV-71. Three recent phase 3 clinical trials of
inactivated monovalent EV-A71 vaccines manufactured in
China were found to have high efficacy (80.4 %–97.4 %)
against EV-A71in infants and young children [72–74], and
two of these vaccines were licensed in China in December
2015 and will be available on the private vaccine market in
China. Although vaccine development for specific pathogens
such as poliovirus and EV-71 is possible, developing vaccines
against all members of the EVand HPeV genera is not feasible
due to the large number of EVs and HPeVs serotypes.
To date, no antiviral drugs have been approved for the
treatment of picornavirus infections and treatment is limited
to supportive care [54]. The only option available for treat-
ment is the administration of intravenous immunoglobulin
(IVIG), but the success rate of this treatment modality is var-
iable and possibly depends on the presence of specific neu-
tralizing antibodies in the preparation [75–78]. Pleconaril is an
oral viral capsid inhibitor with activity against picornaviruses.
Results on the clinical outcome varied considerably from
complete recovery to fatalities. In studies of EV meningitis,
EV infections in immunocompromised hosts, and in a phase 1
study in neonates, pleconaril was generally well tolerated,
with suggestion of benefit in some studies [79–81]. Abzug
et al. performed a randomized controlled trial to the effect of
treatment of pleoconaril in neonates with EV sepsis [82]. They
describe a shorter time to culture and PCR negativity and
greater survival among pleconaril recipients. Further develop-
ment and evaluation of pleconaril in children with EV infec-
tion is still needed.
Prognosis of EV and HPeV infections
Little is known about the prognosis and long-term effects of
EVand HPeV meningitis in children. Only some studies with
a small number of children with EV meningitis are reported.
Sells et al. did a controlled follow-up study in 1975 of 19
children 2.5–8 years of age who had been hospitalized with
documented EV central nervous system infection (aseptic
meningitis in 9, meningoencephalitis in 9 and acute cerebellar
ataxia in 1 child) 17–67 months before evaluation [83]. Three
children (16 %) had definite neurologic impairment, five
(26 %) had possible impairment, and 11 (58 %) were free of
detectable abnormalities. Children whose illness occurred dur-
ing the first year of life, when compared to controls, were
found to have significantly smaller mean head circumference
(50.6 vs. 51.6 cm, p<0.033), significantly lower mean I.Q.
(97 vs 115, p<0.007), and depressed language and speech
skills. Children whose illness occurred after the first year of
life were not different from their controls. They concluded that
children with central-nervous-system enterovirus infection
may have neurologic impairment when infection occurs in
the first year of life.
Wilfert et al. performed a case control study of 9 children
with an EV meningitis during the first 3 months of life [84].
Receptive vocabulary testing suggested that the receptive lan-
guage functioning of the group with meningitis was signifi-
cantly less than that of the control group. There was no sig-
nificant difference in head circumference, no detectable sen-
sorineural hearing loss, and no detected differences in intel-
lectual functioning between the meningitis group andmatched
control subjects.
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Verboon et al. described 6 neonates with EV meningoen-
cephalitis in a neonatal intensive care unit [85]. Five infants
presented with prolonged seizures, and one presented with
systemic EV disease. Cranial ultrasonography showed in-
creased echogenicity in the periventricular white matter, and
MRI confirmed mild to severe white matter damage in all
infants, which looked similar to periventricular leukomalacia.
Two infants developed cerebral palsy: one was neurologically
suspect at age 18 months, and three were developmentally
normal.
Chang et al. described a larger cohort of 142 children after
an EV 71 infection with CNS involvement [62]. 61 who had
aseptic meningitis, 53 who had severe CNS involvement, and
28 who had cardiopulmonary failure after CNS involvement.
Delayed neurodevelopment was found in only 1 of 20 patients
(5 %) with severe CNS involvement and in 21 of 28 patients
(75 %) with cardiopulmonary failure (p<0.001). Children
with cardiopulmonary failure after CNS involvement scored
lower on intelligence tests than did children with CNS in-
volvement alone (p=0.003).
Conclusions
EV and HPeV infections are a major cause of infection in
children. EV and HPeV infection have a great variety of clin-
ical manifestations varying from mild gastrointestinal infec-
tions to more severe diseases like meningitis and sepsis lead-
ing to mortality. The gold standard for diagnosing EV and
HPeV infection is RT-qPCR. No antiviral drugs have been
approved for the treatment of EV or HPeV infections, and
treatment is limited to supportive care. Vaccines to EV-A71
were developed and will be available on the private market in
China soon.
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